Unravelling the Mimicker of Autoimmune Disease: Myelin Oligodendrocyte Glycoprotein (MOG)-Associated Demyelinating Disease in Males

doi:10.5281/zenodo.12781790

International Journal of Medical and Pharmaceutical Research

2025, Volume-6, Issue-1 doi: 10.5281/zenodo.12781790

Case Report

Unravelling the Mimicker of Autoimmune Disease: Myelin Oligodendrocyte Glycoprotein (MOG)-Associated Demyelinating Disease in Males

Dr Rupanshi Jain, Dr Vijaya Rajesh Kamble (Prof), Dr Vishal Gupta (Prof), Dr Sandeep Kumar

DOI : 10.5281/zenodo.12781790

Published

Feb. 23, 2025

Abstract

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a protein found exclusively on the outer surface of myelin sheaths and oligodendrocyte membranes. Because of this specific localization, MOG can become a target for both cellular and humoral immune responses in inflammatory demyelinating diseases. Its expression occurs later in postnatal development, making it a key marker for the maturation of oligodendrocytes. Autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) can result in various autoimmune disorders, including optic neuritis, transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis.In this case report we present a 19 year old male patient presented with complaints of bilateral lower limb numbness with acute urine retention since 1 day.

Recommended Articles

Volume-6, Issue-1

Downloads

Download PDF pdf

Download XML

Citations

679 Views

294 Downloads

Share this article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.